Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study

被引：0
|
作者：
Patorno, Elisabetta
Pawar, Ajinkya
Bessette, Lily G.
Najafzadeh, Mehdi
Wexler, Deborah J.
Franklin, Jessica
Deruaz-Luyet, Anouk
Brodovicz, Kimberly
Koeneman, Lisette
Schneeweiss, Sebastian
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-133-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133-LB
引用
收藏
页数：3
相关论文
共 50 条
  • [21] DPP-4 inhibitors vs GLP-1 receptor agonists after failure of metformin monotherapy in type 2 diabetes
    Hernandez Mijares, A.
    AVANCES EN DIABETOLOGIA, 2010, 26 (04): : 270 - 272
  • [22] The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Dara L. Eckerle Mize
    Marzieh Salehi
    Current Diabetes Reports, 2013, 13 : 307 - 318
  • [23] The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study
    Koro, C. E.
    Sowell, M. O.
    Stender, M.
    Chhabra, P.
    Allen, J. K.
    Krzywy, H. J.
    DIABETOLOGIA, 2013, 56 : S183 - S184
  • [24] Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
    Bihan, Helene
    Ng, Winda L.
    Magliano, Dianna J.
    Shaw, Jonathan E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 27 - 34
  • [25] The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis
    de Wit, Helena M.
    te Groen, Maarten
    Rovers, Maroeska M.
    Tack, Cees J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 301 - 314
  • [26] Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
    Sachinidis, Alexandros
    Nikolic, Dragana
    Stoian, Anca Pantea
    Papanas, Nikolaos
    Tarar, Omer
    Rizvi, Ali A.
    Rizzo, Manfredi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
  • [27] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Enrico Longato
    Barbara Di Camillo
    Giovanni Sparacino
    Lara Tramontan
    Angelo Avogaro
    Gian Paolo Fadini
    Cardiovascular Diabetology, 19
  • [28] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Tramontan, Lara
    Avogaro, Angelo
    Fadini, Gian Paolo
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [29] GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
    Brunton, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2014, 68 (05) : 557 - 567
  • [30] Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Neumiller, Joshua J.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S16 - S29
12345